Effects of erlotinib therapy on 11Cerlotinib uptake in EGFR mutated advanced NSCLC

摘要

BackgroundIn non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using [¹¹C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. However, tumor uptake of [¹¹C]erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were to evaluate tumor [¹¹C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [¹¹C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples.